After a cystic fibrosis 'miracle,' researchers are exploring ways to reach millions more

UAB clinical trials pave way to new cystic fibrosis drug

Successful Phase III trials at UAB contributed to the development of a novel “corrector-potentiator” combination drug therapy for cystic fibrosis patients.

Fixing cystic fibrosis: In vitro studies show therapeutically robust correction of the most common CF gene mutation

Cystic fibrosis lung cells were restored to 50 percent of healthy function in work that provides the first evidence that novel therapeutic strategies for human patients can be identified based on yeast studies.